DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/864tj4/leukemia_drug) has announced the addition of the "Leukemia Drug Pipeline Update 2014" report to their offering.
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented.
There are today 287 companies plus partners developing 401 leukemia drugs in 604 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 126 drugs.
Leukemia Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 268 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 256 out of the 260 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 63 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed # 66
- Registered # 1
- Pre-registration # 2
- Phase III # 27
- Phase II # 144
- Phase I # 127
- Preclinical # 86
- No Data # 8
- Suspended # 5
- Ceased # 126
For more information visit http://www.researchandmarkets.com/research/864tj4/leukemia_drug